Last updated: Wednesday, May 15, 2019


AstraZeneca Announces Partnerships to Benefit Cancer Patients and Prevent Diseases Amongst Youth

Posted: Friday, January 11, 2019

On January 10, AstraZeneca, the global science-led biopharmaceutical company, commemorates its 25th anniversary in Vietnam through a joint announcement with National Cancer Hospital and Plan International, demonstrating the company’s continuous commitment to local patients and healthcare sector.

Nitin Kapoor, Chief Representative of AstraZeneca Singapore Pte. Ltd in Vietnam said: “AstraZeneca is proud to present early in Vietnam and accompany the country’s healthcare development since 1994. The 25th year milestone opens a new chapter for us in Vietnam to strengthen our partnerships and further support the development of innovative solutions to local healthcare needs in non-communicable diseases. Beyond that, we believe that it will take more than medicines alone to tackle the non-communicable disease challenges of the future. We need to focus on investment for youth and prevention now”.

The company’s bond with Vietnam started when it was first licensed in 1994 under Astra, then collaborated with Vietnam Healthcare organisations to conduct Global Phase 3 clinical trial in Vietnam. The global announcement in 1999 has opened up a new chapter of growth in Vietnam for AstraZeneca.

Aligned with the Government’s National Strategy for the Prevention and Control of Non-Communicable Diseases (2015 – 2025), AstraZeneca has focused on accelerating local investment for R&D as well as patients access to innovative healthcare solutions in Oncology, Cardiovascular, Renal and Metabolism, and Respiratory diseases. This includes the company’s US$ 20 million investment in clinical trials during period of 2017- 2019 in Vietnam through a robust network of 132 local clinical research sites. Another example is the partnership with Ministry of Health’s Medical Service Administration (MSA) for the Healthy Lung programme. The US$ 1 million investment, announced in 2017 aims to improve the quality of outpatient management of asthma and Chronic Obstructive Pulmonary Disease (COPD) in Vietnam. The company has also implemented its global ‘Early Action in Diabetes’ program by partnering with Vietnam Young Physicians Association to host Community day 2018, raising awareness for early action in Diabetes in Ha Noi and Ho Chi Minh city.

Enhancing Oncology treatment and patient benefits through collaboration with National Cancer Hospital

Being signed on the company’s 25 years event, the Memorandum of Understanding with National Cancer Hospital aims to address the unmet needs in Oncology diseases treatment during 2019 – 2022. With a vision to transform the lives of cancer patients on lung, breast, ovarian cancer and hematology, and to develop more research to eliminate cancer as a cause of death in the future, the partnership will combine scientific insight and expertise from both sides to provide greatest value for clinical studies and for patients. Both parties have also agreed to collaborate in Continuing Medical Education (CME) for healthcare practitioners and Patient Assistance Program (PAP) according to the Ministry of Health’s regulation and the applicable law.

Nitin Kapoor, Chief Representative of AstraZeneca Singapore Pte. Ltd in Vietnam stressed: “We are honored to partner with National Cancer Hospital to advancing the research in Oncology to deliver life-changing medicines to patients in Vietnam. AstraZeneca looks forward to support the development of local research expertise and Vietnam reputation in international science map.”

Prof. PhD. MD. Tran Van Thuan, Director of National Cancer Hospital shared: “Today's memorandum of understanding is a testament of AstraZeneca's dedication and commitment in scientific research and innovation in Vietnam, especially in cancer treatment. With our leading role, National Cancer Hospital will continue to work closely with AstraZeneca to bring new medical solutions, open new prospects to patients facing cancer and help them fight the disease more effectively.”

Investing in the health of the next generation in Vietnam by partnering with Plan International
On the same occasion, AstraZeneca announces the partnership with Plan International Vietnam to bring an award-winning disease prevention programme to Vietnam - The AstraZeneca Young Health Programme (YHP). This is a global community investment programme focusing on youth and prevention of the most common NCDs: cancer, diabetes, heart disease and respiratory disease.

The YHP Vietnam is a three-year programme that aims to contribute to the improved health and wellbeing of young people between 10 – 24 years of age in Hai Ba Trung District and Dong Anh District of Hanoi. Specifically, it aims to ensure that young people in Hanoi have increased knowledge about risk behaviours and NCD prevention, which gives them greater capacity to make informed decisions about their health, in the context of improved health services, an enabling support system and policy environment.

Aligned with the Government’s National Strategy for the Prevention and Control of NCDs (2015 – 2025), the YHP addresses the primary NCD risk factors of tobacco use, the harmful use of alcohol, physical inactivity, poor diet and air pollution, as well as supporting the broader health and rights of young people.

Sharon Kane, Country Director, Plan International Vietnam said: “In youth, decisions are made, habits are formed, and paths chosen that can have life-long repercussions and impact across generations. Evidence shows that unhealthy behaviour patterns related to NCDs – including unhealthy diets, tobacco use and smoke exposure, physical inactivity, and harmful use of alcohol – are often initiated during childhood and adolescence. To accelerate the response to NCDs worldwide, greater attention and is needed in these early years of life. As such, we are proud to work with our global partner AstraZeneca to bring YHP to Vietnam.”

Globally, the YHP has reached more than 2.25 million youth in more than 20 countries across 5 continents since it was launched in 2010. In 2018, the YHP was recognized by Ethical Corporate when it was named Community Investment Programme of the Year award in the Responsible Business Awards.

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.


Other news

Yen sao Khanh Hoa
My Le
Vietnam Export Gateway
Tong cu DL